EUNew treatments and approvals
EU approval of marstacimab extended to hemophilia A and B with inhibitors
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The European Commission extended the use of marstacimab to also cover patients with hemophilia A with factor VIII inhibitors and hemophilia B with factor IX inhibitors. The approval applies to patients aged 12 years and older who weigh at least 35 kg. The drug is injected under the skin once a week.
What does it mean for patients and families?
A new preventive treatment route has opened in Europe. This route is for patients who have developed inhibitors and have limited options. Availability in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
BioSpace (Pfizer) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Hemophilia (A and B)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.